APG-157 plus Avastin for recurrent high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a high-grade (grade III or IV) brain tumor that has gotten worse despite treatment with bevacizumab (Avastin).
- You have had radiation and temozolomide chemotherapy in the past.
- You are 19 years or older and have recovered from any side effects of previous treatments.
- Your blood counts, kidney function, and liver function must be within a safe range.
- You cannot be pregnant or nursing, and must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
This trial tests a combination of two medications—irinotecan liposomes (a chemotherapy drug wrapped in fat particles) and bevacizumab (a drug that cuts off blood supply to tumors)—for people whose glioma (a type of brain tumor) has come back or worsened after initial treatment. The goal is to see if this combination can help control the tumor.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
This trial tests whether using special MRI information to plan proton radiation, plus a drug called Avastin (bevacizumab), can help control recurrent glioblastoma (a fast-growing brain tumor) and improve outcomes. It mainly aims to treat tumor that has come back after prior standard radiation, using careful timing and imaging to target it safely.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.